Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) This autumn 2022 Earnings Convention Name March 2, 2023 4:30 PM ET

Firm Members

Mariann Ohanesian – Senior Director of IR

Alan Auerbach – CEO, President and Chairman

Maximo Nougues – CFO

Jeff Ludwig – Chief Business Officer

Convention Name Members

Dave Rao – Cowen and Firm

Sahil Kazmi – B. Riley Securities


Good afternoon. My identify is Diego, and I might be your convention name operator in the present day. [Operator Instructions] As a reminder, this name is being recorded.

I’d now like to show the convention name over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. It’s possible you’ll start your convention.

Mariann Ohanesian

Thanks, Diego. Good afternoon and welcome to Puma’s convention name to debate our monetary outcomes for the fourth quarter and full 12 months 2022. Becoming a member of me on the decision in the present day are Alan Auerbach, Chief Govt Officer, President and Chairman of the Board of Puma; Maximo Nougues, Chief Monetary Officer; and Jeff Ludwig, Chief Business Officer.

After market closed in the present day, Puma issued a information launch detailing fourth quarter 2022 monetary outcomes. That information launch, the slides that Jeff will consult with and a webcast of this name are accessible by way of the homepage and Buyers sections of our web site at pumabiotechnology.com. The webcast and presentation slides might be archived on our web site and obtainable for replay for the following 90 days.

As we speak’s convention name will embrace statements concerning the firm’s future expectations, plans and prospects that represent forward-looking statements for functions of federal securities legal guidelines. Such statements are topic to dangers and uncertainties and precise occasions and outcomes might differ from these expressed in these forward-looking statements. For a full dialogue of those dangers and uncertainties, please assessment our periodic and present experiences filed with the SEC every so often, together with our annual report on Kind 10-Ok